Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Xylem, Inc. — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.33 (market cap $2.27B), while Xylem, Inc. trades at $102.3 (market cap $23.81B). The key difference: Xylem, Inc. is far larger — about 10.5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Xylem, Inc. pays a 1.69% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| SLS | XYL | |
|---|---|---|
Market Cap | $2.27B | $23.81B |
Volume | 4,179,659 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $15.46 | $152.95 |
52-Week Low | $1.39 | $100.92 |
Enterprise Value | $2.14B | $25.59B |
Typical Hold Time | — | 50 Days |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XYL trades at $101.83, down 2.63% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results due October 27. Revenue grew to $9.04B in 2025, with net income margin improving to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
Outlook remains positive due to strong water-solutions demand and margin expansion, though near-term sentiment is cautious amid China weakness and higher debt from recent note offerings. The consensus price target of $149.13 implies significant upside, but investors should monitor execution risks and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
